journal article·2024-12-11Open access

PEG-PLGA core–shell nanoparticles for the controlled delivery of picoplatin–hydroxypropyl β-cyclodextrin inclusion complex in triple-negative breast cancer: In vitro and in vivo study

Mohamed S. Nafie, Nada K. Sedky, Hatem A. F. M. Hassan, Iten M. Fawzy, Manal M. M. Abdelhady, Udo Bakowsky, Sherif Ashraf Fahmy

Nanotechnology Reviews· Volume 13· Issue 1

Abstract

Abstract In this study, we prepared an inclusion complex of picoplatin (Pc) with 2-hydroxy propyl β cyclodextrin (HPCD) to improve its hydrophilicity, yielding Pc-HPCD. The Pc-HPCD complex was encapsulated into PEG-PLGA nanoparticles (NPs) using the emulsion–solvent evaporation method, yielding Pc-HPCD@PEG-PLGA core–shell NPs. The inclusion complex was assessed using 1 HNMR spectroscopy and a phase solubility study. In addition, the average hydrodynamic diameter, polydispersity index, zeta potential, and encapsulation efficiency (EE%) of the Pc-HPCD@PEG-PLGA NPs were 190.2 ± 8.7 nm, 0.14 ± 0.02, −13.97 ± 0.67 mV, and 80.7 ± 2.4%, respectively. In vitro release study showed a pH-triggered release manner. Furthermore, the biological evaluation of Pc-HPCD@PEG-PLGA NPs revealed a significantly potent cytotoxic activity (IC 50 = 1.6 ± 0.24 µg/ml) against triple-negative breast cancer cells (TNBC), surpassing that of Pc-HPCD (IC 50 = 5.3 ± 0.93 µg/ml) and Pc (IC 50 = 7.5 ± 0.4 µg/ml). Pc-HPCD@PEG-PLGA NPs induced significant apoptosis and the ability to arrest cells at the sub-G1 phase in MDA-MB-231 cells. Moreover, in an in vivo model established using SEC-bearing mice, treatment with Pc-HPCD@PEG-PLGA demonstrated significant inhibition of tumor proliferation (67.2%). This was accompanied by improvements in hematological and biochemical measurements, as well as histopathological examination, which indicated a reduction in cellular and nuclear pleomorphism. Our study demonstrated the potential of Pc-HPCD@PEG-PLGA NPs to be employed as an effective and safe therapy capable of conquering TNBC.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Graphene and Nanomaterials Applications · Advanced Drug Delivery Systems

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Chemistry, College of Sciences, University of Sharjah , Sharjah , P.O. 27272 , United Arab Emirates

Department of Biochemistry, School of Life and Medical Sciences, University of Hertfordshire Hosted by Global Academic Foundation, R5 New Garden City, New Administrative Capital , Cairo , 11835 , Egypt

Medway School of Pharmacy, University of Kent, Chatham Maritime , Kent , ME4 4TB , United Kingdom

Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University , 11562 , Cairo , Egypt

Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Future University in Egypt , 11835 , Cairo , Egypt

Clinical Pharmacy Department, Faculty of Pharmacy, Badr University , Cairo , 11829 , Egypt

Department of Pharmaceutics and Biopharmaceutics, University of Marburg , Robert-Koch-Str. 4, 35037 , Marburg , Germany

Department of Chemistry, School of Life and Medical Sciences, University of Hertfordshire Hosted by Global Academic Foundation, R5 New Garden City, New Capital , Cairo , 11835 , Egypt

References (50)

Show source-provided references
1. Fahmy SA, Dawoud A, Zeinelabdeen YA, Kiriacos CJ, Daniel KA, Eltahtawy O, et al. Molecular engines, therapeutic targets, and challenges in pediatric brain tumors: a special emphasis on hydrogen sulfide and rna-based nano-delivery. Cancers. 2022;14:5244.10.3390/cancers14215244 ↗
2. Ayoub AM, Atya MS, Abdelsalam AM, Schulze J, Amin MU, Engelhardt K, et al. Photoactive Parietin-loaded nanocarriers as an efficient therapeutic platform against triple-negative breast cancer. Int J Pharm. 2023;643:123217.10.1016/j.ijpharm.2023.123217 ↗
3. Fahmy SA, Ponte F, Grande G, Fawzy IM, Mandour AA, Sicilia E, et al. Synthesis, characterization and host-guest complexation of asplatin: improved in vitro cytotoxicity and biocompatibility as compared to cisplatin. Pharmaceuticals. 2022;15:259.10.3390/ph15020259 ↗
4. Ritacco I, Al Assy M, Abd El-Rahman MK, Fahmy SA, Russo N, Shoeib T, et al. Hydrolysis in acidic environment and degradation of satraplatin: a joint experimental and theoretical investigation. Inorg Chem. 2017;56:6013–26.10.1021/acs.inorgchem.7b00945 ↗
5. Sedky NK, Arafa KK, Abdelhady MMM, Issa MY, Abdel-Kader NM, Mahdy NK, et al. Nedaplatin/peganum harmala alkaloids co-loaded electrospun, implantable nanofibers: a chemopreventive nano-delivery system for treating and preventing breast cancer recurrence after tumorectomy. Pharmaceutics. 2023;15:2367.10.3390/pharmaceutics15102367 ↗
6. Fahmy SA, Preis E, Dayyih AA, Alawak M, El-Said Azzazy HM, Bakowsky U, et al. Thermosensitive liposomes encapsulating nedaplatin and picoplatin demonstrate enhanced cytotoxicity against breast cancer cells. ACS Omega. 2022;7:42115–25.10.1021/acsomega.2c04525 ↗
7. Holford J, Raynaud F, Murrer BA, Grimaldi K, Hartley JA, Abrams M, et al. Chemical, biochemical and pharmacological activity of the novel sterically hindered platinum co-ordination complex, cis-[amminedichloro(2-methylpyridine)] platinum(II) (AMD473). Anticancer Drug Des. 1998;13:1–18.
8. Fahmy SA, Mahdy NK, Al Mulla H, ElMeshad AN, Issa MY, Azzazy HME. PLGA/PEG nanoparticles loaded with cyclodextrin-peganum harmala alkaloid complex and ascorbic acid with promising antimicrobial activities. Pharmaceutics. 2022;14:142.10.3390/pharmaceutics14010142 ↗
9. Liang B, Hao J, Zhu N, Han L, Song L, Hong H. Formulation of nitrendipine/hydroxypropyl-β-cyclodextrin inclusion complex as a drug delivery system to enhance the solubility and bioavailability by supercritical fluid technology. Eur Polym J. 2023;187:111880.10.1016/j.eurpolymj.2023.111880 ↗
10. Mai Y, Eisenberg A. Self-assembly of block copolymers. Chem Soc Rev. 2012;41:5969–85.10.1039/c2cs35115c ↗
11. Rafiei P, Haddadi A. Docetaxel-loaded PLGA and PLGA-PEG nanoparticles for intravenous application: pharmacokinetics and biodistribution profile. Int J Nanomed. 2017;12:935–47.10.2147/IJN.S121881 ↗
12. Mares AG, Pacassoni G, Marti JS, Pujals S, Albertazzi L. Formulation of tunable size PLGA-PEG nanoparticles for drug delivery using microfluidic technology. PLoS One. 2021;16:e0251821.10.1371/journal.pone.0251821 ↗
13. Plenagl N, Seitz BS, Duse L, Pinnapireddy SR, Jedelska J, Brussler J, et al. Hypericin inclusion complexes encapsulated in liposomes for antimicrobial photodynamic therapy. Int J Pharm. 2019;570:118666.10.1016/j.ijpharm.2019.118666 ↗
14. Ponte F, Sedky NK, Fawzy IM, Mokhtar F, Sicilia E, Fahmy SA. Psoralidin–cucurbit[7]uril complex with improved solubility to tackle human colorectal cancer: experimental and computational study. Mater Adv. 2023;4:5324–37.10.1039/D3MA00521F ↗
15. Mader WJ, Higuchi T. Phase solubility analysis. Crit Rev Anal Chem. 1970;1:193–215.10.1080/10408347008085634 ↗
16. Fahmy SA, Nematallah KA, Mahdy NK, El-Askary HI, Meselhy MR, El-Said Azzazy HM. Enhanced antioxidant, antiviral, and anticancer activities of the extract of fermented egyptian rice bran complexed with hydroxypropyl-beta-cyclodextrin. ACS Omega. 2022;7:19545–54.10.1021/acsomega.2c01281 ↗
17. Haggag Y, Abdel-Wahab Y, Ojo O, Osman M, El-Gizawy S, El-Tanani M, et al. Preparation and in vivo evaluation of insulin-loaded biodegradable nanoparticles prepared from diblock copolymers of PLGA and PEG. Int J Pharm. 2016;499:236–46.10.1016/j.ijpharm.2015.12.063 ↗
18. Wang H, Zhao Y, Wu Y, Hu YL, Nan K, Nie G, et al. Enhanced antitumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles. Biomaterials. 2011;32:8281–90.10.1016/j.biomaterials.2011.07.032 ↗
19. Fahmy SA, Ramzy A, Sawy AM, Nabil M, Gad MZ, El-Shazly M, et al. Ozonated olive oil: enhanced cutaneous delivery via niosomal nanovesicles for melanoma treatment. Antioxidants (Basel). 2022;11(7):1318.10.3390/antiox11071318 ↗
20. Youness RA, Al-Mahallawi AM, Mahmoud FH, Atta H, Braoudaki M, Fahmy SA. Oral delivery of psoralidin by mucoadhesive surface-modified bilosomes showed boosted apoptotic and necrotic effects against breast and lung cancer cells. Polymers. 2023;15:1464.10.3390/polym15061464 ↗
21. Fahmy SA, Sedky NK, Ramzy A, Abdelhady MMM, Alabrahim OAA, Shamma SN, et al. Green extraction of essential oils from Pistacia lentiscus resins: Encapsulation into Niosomes showed improved preferential cytotoxic and apoptotic effects against breast and ovarian cancer cells. J Drug Delivery Sci Technol. 2023;87:104820.10.1016/j.jddst.2023.104820 ↗
22. Fahmy SA, Fawzy IM, Saleh BM, Issa MY, Bakowsky U, Azzazy HME. Green synthesis of platinum and palladium nanoparticles using peganum harmala l. seed alkaloids: biological and computational studies. Nanomaterials (Basel). 2021;11(4):965.10.3390/nano11040965 ↗
23. Sedky NK, Abdel-Kader NM, Issa MY, Abdelhady MMM, Shamma SN, Bakowsky U, et al. Co-delivery of ylang ylang oil of cananga odorata and oxaliplatin using intelligent ph-sensitive lipid-based nanovesicles for the effective treatment of triple-negative breast cancer. Int J Mol Sci. 2023;24(9):8392.10.3390/ijms24098392 ↗
24. Azzazy HME-S, Sawy AM, Abdelnaser A, Meselhy MR, Shoeib T, Fahmy SA. Peganum harmala alkaloids and tannic acid encapsulated in PAMAM dendrimers: improved anticancer activities as compared to doxorubicin. ACS Appl Polym Mater. 2022;4:7228–39.10.1021/acsapm.2c01093 ↗
25. Attia RT, Ewida MA, Khaled E, Fahmy SA, Fawzy IM. Newly synthesized anticancer purine derivatives inhibiting p-eif4e using surface-modified lipid nanovesicles. ACS Omega. 2023;8:37864–81.10.1021/acsomega.3c02991 ↗
26. AbuBakr AH, Hassan H, Abdalla A, Khowessah OM, Abdelbary GA. Therapeutic potential of cationic bilosomes in the treatment of carrageenan-induced rat arthritis via fluticasone propionate gel. Int J Pharm. 2023;635:122776.10.1016/j.ijpharm.2023.122776 ↗
27. Yuan JH, Yang F, Wang F, Ma JZ, Guo YJ, Tao QF, et al. A long noncoding RNA activated by TGF-beta promotes the invasion-metastasis cascade in hepatocellular carcinoma. Cancer Cell. 2014;25:666–81.10.1016/j.ccr.2014.03.010 ↗
28. Tzeyung AS, Md S, Bhattamisra SK, Madheswaran T, Alhakamy NA, Aldawsari HM, et al. Fabrication, optimization, and evaluation of rotigotine-loaded chitosan nanoparticles for nose-to-brain delivery. Pharmaceutics. 2019;11(1):26.10.3390/pharmaceutics11010026 ↗
29. Abonashey SG, Hassan H, Shalaby MA, Fouad AG, Mobarez E, El-Banna HA. Formulation, pharmacokinetics, and antibacterial activity of florfenicol-loaded niosome. Drug Delivery Transl Res. 2024;14:1077–92.10.1007/s13346-023-01459-9 ↗
30. Li B, Shan M, Di X, Gong C, Zhang L, Wang Y, et al. A dual pH- and reduction-responsive anticancer drug delivery system based on PEG–SS–poly(amino acid) block copolymer. RSC Adv. 2017;7:30242–9.10.1039/C7RA04254J ↗
31. Khalifa MM, Al-Karmalawy AA, Elkaeed EB, Nafie MS, Tantawy MA, Eissa IH, et al. Topo II inhibition and DNA intercalation by new phthalazine-based derivatives as potent anticancer agents: design, synthesis, anti-proliferative, docking, and in vivo studies. J Enzyme Inhib Med Chem. 2022;37:299–314.10.1080/14756366.2021.2007905 ↗
32. Boraei ATA, Eltamany EH, Ali IAI, Gebriel SM, Nafie MS. Synthesis of new substituted pyridine derivatives as potent anti-liver cancer agents through apoptosis induction: In vitro, in vivo, and in silico integrated approaches. Bioorganic Chem. 2021;111:104877.10.1016/j.bioorg.2021.104877 ↗
33. Nafie MS, Elghazawy NH, Owf SM, Arafa K, Abdel-Rahman MA, Arafa RK. Control of ER-positive breast cancer by ERalpha expression inhibition, apoptosis induction, cell cycle arrest using semisynthetic isoeugenol derivatives. Chem Biol Interact. 2022;351:109753.10.1016/j.cbi.2021.109753 ↗
34. Zhang J-Q, Li K, Cong Y-W, Pu S-P, Zhu H-Y, Xie X-G, et al. Preparation, characterisation and bioactivity evaluation of the inclusion complex formed between picoplatin and γ-cyclodextrin. Carbohydr Res. 2014;396:54–61.10.1016/j.carres.2014.07.015 ↗
35. Dayyih AA, Gutberlet B, Preis E, Engelhardt KH, Amin MU, Abdelsalam AM, et al. Thermoresponsive liposomes for photo-triggered release of hypericin cyclodextrin inclusion complex for efficient antimicrobial photodynamic therapy. ACS Appl Mater interfaces. 2022;14:31525–40.10.1021/acsami.2c02741 ↗
36. Kurkov SV, Ukhatskaya EV, Loftsson T. Drug/cyclodextrin: beyond inclusion complexation. J Inclusion Phenom Macrocyclic Chem. 2011;69:297–301.10.1007/s10847-010-9756-x ↗
37. Fahmy SA, Ponte F, Abd El-Rahman MK, Russo N, Sicilia E, Shoeib T. Investigation of the host-guest complexation between 4-sulfocalix[4]arene and nedaplatin for potential use in drug delivery. Spectrochim Acta, Part A. 2018;193:528–36.10.1016/j.saa.2017.12.070 ↗
38. Praetorius A, Bailey DM, Schwarzlose T, Nau WM. Design of a fluorescent dye for indicator displacement from cucurbiturils: a macrocycle-responsive fluorescent switch operating through a pKa shift. Org Lett. 2008;10:4089–92.10.1021/ol8016275 ↗
39. Wheate NJ, Abbott GM, Tate RJ, Clements CJ, Edrada-Ebel R, Johnston BF. Side-on binding of p-sulphonatocalix[4]arene to the dinuclear platinum complex trans-[{PtCl(NH3)2}2μ-dpzm]2 + and its implications for anticancer drug delivery. J Inorg Biochem. 2009;103:448–54.10.1016/j.jinorgbio.2008.12.011 ↗
40. Martinho N, Marques JMT, Todoriko I, Prieto M, de Almeida RFM, Silva LC. Effect of cisplatin and its catonic analogues in the phase behavior and permeability of model lipid bilayers. Mol Pharm. 2023;20:918–28.10.1021/acs.molpharmaceut.2c00321 ↗
41. Justus CR, Dong L, Yang LV. Acidic tumor microenvironment and pH-sensing G protein-coupled receptors. Front Physiol. 2013;4:354.10.3389/fphys.2013.00354 ↗
42. Kato Y, Ozawa S, Miyamoto C, Maehata Y, Suzuki A, Maeda T, et al. Acidic extracellular microenvironment and cancer. Cancer Cell Int. 2013;13:89.10.1186/1475-2867-13-89 ↗
43. Kwon YJ, Seo EB, Jeong AJ, Lee SH, Noh KH, Lee S, et al. The acidic tumor microenvironment enhances PD-L1 expression via activation of STAT3 in MDA-MB-231 breast cancer cells. BMC Cancer. 2022;22:852.10.1186/s12885-022-09956-9 ↗
44. Tang CH, Parham C, Shocron E, McMahon G, Patel N. Picoplatin overcomes resistance to cell toxicity in small-cell lung cancer cells previously treated with cisplatin and carboplatin. Cancer Chemother Pharmacol. 2011;67:1389–400.10.1007/s00280-010-1435-5 ↗
45. Zhang D, Zhang J, Jiang K, Li K, Cong Y, Pu S, et al. Preparation, characterisation and antitumour activity of beta-, gamma- and HP-beta-cyclodextrin inclusion complexes of oxaliplatin. Spectrochim Acta A Mol Biomol Spectrosc. 2016;152:501–8.10.1016/j.saa.2015.07.088 ↗
46. Sokol MB, Chirkina MV, Yabbarov NG, Mollaeva MR, Podrugina TA, Pavlova AS, et al. Structural optimization of platinum drugs to improve the drug-loading and antitumor efficacy of PLGA nanoparticles. Pharmaceutics. 2022;14(11):2333.10.3390/pharmaceutics14112333 ↗
47. Al Jayoush AR, Hassan HAFM, Asiri H, Jafar M, Saeed R, Harati R, et al. Niosomes for nose-to-brain delivery: A non-invasive versatile carrier system for drug delivery in neurodegenerative diseases. J Drug Delivery Sci Technol. 2023;89:105007.10.1016/j.jddst.2023.105007 ↗
48. Ma G, Kostevsek N, Monaco I, Ruiz A, Markelc B, Cheung CCL, et al. PD1 blockade potentiates the therapeutic efficacy of photothermally-activated and MRI-guided low temperature-sensitive magnetoliposomes. J Controlled Release. 2021;332:419–33.10.1016/j.jconrel.2021.03.002 ↗
49. Sedky NK, Mahdy NK, Abdel-kader NM, Abdelhady MMM, Maged M, Allam AL, et al. Facile sonochemically-assisted bioengineering of titanium dioxide nanoparticles and deciphering their potential in treating breast and lung cancers: biological, molecular, and computational-based investigations. RSC Adv. 2024;14:8583–601.10.1039/D3RA08908H ↗
50. Ayoub AM, Amin MU, Ambreen G, Dayyih AA, Abdelsalam AM, Somaida A, et al. Photodynamic and antiangiogenic activities of parietin liposomes in triple negative breast cancer. Biomater Adv. 2022;134:112543.10.1016/j.msec.2021.112543 ↗